EU and US could reach trade deal this weekend - Reuters
Citizens JMP analyst reiterated a Market Outperform rating and $28.00 price target on Kura Oncology (NASDAQ:KURA), currently valued at $577 million, following the presentation of clinical trial results at the 2025 EHA Annual Meeting. According to InvestingPro data, analysts maintain a strong buy consensus with targets ranging from $8 to $40.
The KOMET-007 trial evaluated ziftomenib (zifto) in combination with 7+3 chemotherapy as a treatment for first-line acute myeloid leukemia (AML). The trial demonstrated a 92% complete remission composite (CRc) rate and 76% complete remission with minimal residual disease negativity.
The safety profile of the combination therapy was reported to be similar to the standard of care treatment alone, according to data presented at the meeting.
Kura’s ziftomenib is on track for potential regulatory approval in the fourth quarter of 2025, with a Prescription Drug User Fee Act (PDUFA) date of November 30. The company plans to initiate frontline trials in the second half of 2025.
The firm noted that Kura maintains a strong financial position with a pro forma cash position of $703.2 million, while its stock currently trades at an enterprise value of negative $126 million. With a current ratio of 8.07 and more cash than debt on its balance sheet, InvestingPro rates the company’s overall financial health as ’Fair’. Get access to 10+ additional ProTips and comprehensive financial analysis in the Pro Research Report.
In other recent news, Kura Oncology has announced significant developments surrounding its investigational drug, ziftomenib, aimed at treating relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ziftomenib and granted it priority review status, with a target action date set for November 30, 2025. This follows positive results from the Phase 2 KOMET-001 trial, which demonstrated a 23% complete remission rate and a favorable safety profile. Analysts from H.C. Wainwright, Citizens JMP, Leerink Partners, and Cantor Fitzgerald have all reiterated positive ratings for Kura Oncology, reflecting confidence in the company’s strategic direction. The KOMET-001 trial results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, providing further insights into the drug’s efficacy and safety. Kura Oncology is also preparing for the release of updated Phase Ib data from the KOMET-007 study, which combines ziftomenib with intensive chemotherapy for first-line AML treatment. The company, in collaboration with Kyowa Kirin, is focusing on advancing its clinical programs and preparing for potential commercialization efforts. These developments indicate a promising trajectory for Kura Oncology as it aims to address unmet needs in the AML treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.